ストックスクリーナーアプリを入手
25.01
0.81%
0.20
アフターアワーズ：
24.42
-0.59
-2.36%
前日終値:
$24.81
開ける：
$24.96
24時間の取引高:
1.48M
Relative Volume:
0.72
時価総額：
$2.46B
収益：
$672.72M
当期純損益:
$-575.44M
株価収益率:
-4.2854
EPS:
-5.8361
ネットキャッシュフロー:
$-487.00M
1週間 パフォーマンス:
+1.96%
1か月 パフォーマンス:
+11.40%
6か月 パフォーマンス:
-21.52%
1年 パフォーマンス:
-35.66%
1日の値動き範囲:
$24.45
$25.32
1週間の範囲:
$23.71
$25.32
52週間の値動き範囲:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
25.01 | 2.44B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | ダウングレード | Goldman | Buy → Neutral |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights - Yahoo Finance
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS - MarketBeat
Earnings call transcript: Ultragenyx Q1 2026 results miss forecasts By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript - Benzinga
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance Singapore
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
ULTRAGENYX PHARMACEUTICAL ($RARE) Releases Q1 2026 Earnings - Quiver Quantitative
Ultragenyx: Q1 Earnings Snapshot - KING5.com
Two FDA decisions by September put Ultragenyx gene therapies in focus - Stock Titan
Gene therapy reviews and Q1 2026 results at Ultragenyx (RARE) - Stock Titan
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update - The Manila Times
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 Shares - MarketBeat
Ultragenyx CFO Howard Horn sells $116,606 in company stock - Investing.com
Ultragenyx (RARE) CFO trims stake with 4,683-share open-market sale - Stock Titan
MSN Money - MSN
Mucopolysaccharidoses Market to Reach USD 4,389.85 Million - openPR.com
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Momentum And Ongoing Losses - Sahm
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street Zen - MarketBeat
Affiliate sales notice for RARE (NASDAQ: RARE) lists recent Howard Horn transactions - Stock Titan
Pictet Asset Management Holding SA Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx falls as guidance trails consensus amid job cuts - MSN
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Rare's DTX301 meets first key goal in Phase III OTC deficiency study - MSN
Vanguard Portfolio Management discloses 5.5% stake in Ultragenyx (RARE) - Stock Titan
Ultragenyx earnings: What to watch as pipeline faces key test By Investing.com - Investing.com India
Ultragenyx earnings: What to watch as pipeline faces key test - Investing.com
Barclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat
RARE Maintained by Barclays -- Price Target Lowered to $43 - GuruFocus
Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial - Yahoo Finance
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update - marketscreener.com
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rare rises as FDA accepts resubmitted BLA for Sanfilippo syndrome - MSN
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
FDA decision on UX111 gene therapy for Sanfilippo expected in September - Sanfilippo Syndrome News
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA - MSN
RARE stock slumps on multiple Wall Street price target slashes, clinical pipeline uncertainty - MSN
Teacher Retirement System of Texas Purchases 327,502 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Above 50-Day Moving AverageHere's Why - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ultragenyx (RARE) SVP Huizenga awarded RSUs and option grant - Stock Titan
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(RARE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Is Ultragenyx Pharmaceutical (RARE) Now Attractive After Recent 8.1% Weekly Share Price Jump - Sahm
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):